Keywords: exenatide, glp-1 receptor agonists, liraglutide, long-term treatment, obesity management, randomized controlled trials, safety profile, semaglutide, sustained weight loss, tirzepatide Introduction and background Obesity has emerged as a global epidemic, with the World Health Organization estimating that over one billion people worldwide are currently classified as overweight or obese
If you eat below your BMR for extended periods, your body begins breaking down muscle for fuel, which lowers your BMR further over time
Ongoing monitoring is built into the program structure, not limited to the initial intake
Most users report feeling reduced effects 8-10 days after injection, with minimal therapeutic benefit by days 12-14